Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05701254 · ClinicalTrials.gov registry record

Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk

A clinical trial of Type 1 Diabetes and Bone Loss, sponsored by Creighton University.

Recruiting
Registry status
80
Enrollment target
1
Study location

NCT05701254: Recruiting study of Type 1 Diabetes and Bone Loss, sponsored by Creighton University.

NCT05701254 is a study of Type 1 Diabetes and Bone Loss that is actively recruiting participants, run by Creighton University. The registered enrollment target is 80 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05701254, a study of Type 1 Diabetes and Bone Loss, is actively recruiting participants, sponsored by Creighton University.

RECRUITING
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

Patients with Type 1 Diabetes Mellitus (T1DM) have a higher risk of low-trauma (osteoporotic) fracture that is 7-12 times higher than non-diabetics. The bone density of people with Type 1 Diabetes is higher at the time of fracture than in non-diabetics. This suggests the presence of underlying bone tissue mechanical defects. The potential benefits to participants would be knowledge gained about their bone density and the results of laboratory tests. On a wider scale, there may be general benefits to society because the knowledge gained from this study may help better understand the effects of diabetes on bone health

Primary Outcome

For different advance glycation endproducts (AGEs), a) pentosidine (PEN), b) pyrinoline (Pyd), and c) tissue water (TW), will be measured using Raman spectroscopy technique on bone biopsy tissue obtained from study participants. Raman spectra will be obtained from the embedded block surfaces using a confocal Raman spectrometer (Renishaw InVia Qontor, www.renishaw.de). These spectra will be collected at the interstitial, cement lines, and actively bone forming osteons with evident fluorescent lab

Interventions

  • PROCEDURE Transilial bone biopsy

Study Locations (1)

Nebraska

  • Creighton University Osteoporosis Research Center - Omaha

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2019-06-18
Est. Completion 2025-01
Creighton University

98 total trials

What NCT05701254 shows while recruiting

NCT05701254 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (90% lower).

The record links to 4 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Transilial bone biopsy is the first listed.

NCT05701254 reports a single indexed study location in Nebraska.

Frequently Asked Questions

What is clinical trial NCT05701254 about?

NCT05701254 is a clinical study titled "Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk". Patients with Type 1 Diabetes Mellitus (T1DM) have a higher risk of low-trauma (osteoporotic) fracture that is 7-12 times higher than non-diabetics. The bone density of people with Type 1 Diabetes is higher at the time of fracture than in non-diabetics. This suggests the presence of underlying bone ...

What is the current status of trial NCT05701254?

This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2019-06-18. Estimated completion is 2025-01.

What conditions does trial NCT05701254 study?

This clinical trial studies the following conditions: Type 1 Diabetes, Bone Loss, Fractures, Bone, Osteopenia.

What interventions are being tested in trial NCT05701254?

The interventions under investigation include: Transilial bone biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT05701254?

This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05701254 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05701254's enrollment target sits among peer trials

80 63rd of 198 higher than 133 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05701254, the US trial registry maintained by the National Library of Medicine. NCT05701254 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.